Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medinol CE-marks pre-mounted NIRFLEX stent:

This article was originally published in Clinica

Executive Summary

Israeli company Medinol has gained CE-mark approval to sell its next-generation, pre-mounted NIRFLEX coronary and peripheral stent in an estimated $500 million European marketplace. The device, which is based on a uniform matrix closed cell design, provides an optimal platform for the even release of drugs that are intended to prevent restenosis, says Medinol. Additionally, the Jerusalem-based firm has gained US FDA go-ahead to begin recruitment into US trials of the NIRFLEX stent, which are scheduled to begin in May this year.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts